Depending on the PD-L1 expression status, these innovative combination treatment regimens should be considered viable choices for ESCC patients, emphasizing the importance of early discovery of these predictive biomarkers to achieve optimal patient outcomes. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.